BUTABARBITAL Drug Patent Profile
✉ Email this page to a colleague
When do Butabarbital patents expire, and what generic alternatives are available?
Butabarbital is a drug marketed by Bundy, Wockhardt, Sandoz, Solvay, Teva, Watson Labs, and Whiteworth Town Plsn. and is included in sixteen NDAs.
The generic ingredient in BUTABARBITAL is butabarbital sodium. There are nine drug master file entries for this compound. Additional details are available on the butabarbital sodium profile page.
Summary for BUTABARBITAL
US Patents: | 0 |
Applicants: | 7 |
NDAs: | 16 |
Raw Ingredient (Bulk) Api Vendors: | 29 |
Clinical Trials: | 1 |
Patent Applications: | 3,578 |
Formulation / Manufacturing: | see details |
DailyMed Link: | BUTABARBITAL at DailyMed |
Recent Clinical Trials for BUTABARBITAL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Federal University of São Paulo | Phase 4 |
Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for BUTABARBITAL
US Patents and Regulatory Information for BUTABARBITAL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bundy | BUTABARBITAL | butabarbital sodium | TABLET;ORAL | 085550-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Solvay | BUTABARBITAL SODIUM | butabarbital sodium | TABLET;ORAL | 083606-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sandoz | BUTABARBITAL SODIUM | butabarbital sodium | TABLET;ORAL | 085938-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |